



ASX Release

Attendance at ESHRE Conference in Spain generates interest from selected, pre-eminent IVF clinics to conduct *in-vitro* studies with Felix device to demonstrate sperm separation efficacy

Highlights

- **Memphasys senior executives recently attended the European Society for Human Reproduction & Embryology (ESHRE) Conference in Barcelona, Spain**
 - **At the conference, executives met and progressed discussions with a range of European and Middle East-based Key Opinion Leaders (“KOLs”)**
 - **Subject to executing apposite agreements, the Felix clinical device will be placed into selected leading KOL IVF clinics globally to enable *in-vitro* studies to be conducted to assess and confirm its performance in selecting and preparing the most viable sperm for IVF treatments**
 - **The Company expects to execute MOUs with KOLs in the September 2018 Quarter, as planned, with *in-vitro* studies to commence in the first quarter of calendar year 2019**
-

Sydney, 19 July 2018: A delegation of senior executives of Memphasys (**ASX: MEM**) (“Memphasys” or “the Company”), and key scientific and clinical advisors to the Company, attended the European Society for Human Reproduction & Embryology (ESHRE) Conference in Barcelona, Spain.

The purpose of this delegation, led by Memphasys Executive Chairman, Alison Coutts and attended by world renowned fertility expert, Prof John Aitken, a key scientific advisor to the Company and head of the Research Centre for Reproductive Science at the University of Newcastle, was to meet with leading KOL IVF clinics and progress discussions focused on having these IVF clinics undertake *in-vitro* assessments using the Felix device, currently in development, and to assess its ability to select the most viable sperm for human IVF treatments.

The Felix device being commercialised by the Company separates the most viable sperm in a semen sample for use in human IVF treatments and provides unique and critical advantages over current sperm processing methods.

Discussions with a range of European and Middle Eastern-based KOLs progressed positively, with the Company expected to enter into MOUs with several leading KOLs in the current September 2018 quarter.

After entering into agreements for clinical assessment by selected KOL clinics, the Felix clinical device will be placed into the clinics to enable *in-vitro* studies to be conducted. The studies will assess and confirm Felix’s performance in preparing sperm from diverse semen types for IVF when compared with the current lab-based methods which are labor intensive, costly and contribute to sperm DNA damage

The outcomes of these studies will provide further evidence as to the technical capabilities and clinical benefits of the Felix device, provide significant user examples of range of use and further define the commercialisation strategy of the Company.

Commenting on the attendance at the ESHRE and the quantity and quality of meetings held with KOLs, MEM Chairman Alison Coutts said: "Attending such a significant global conference and meeting with leading IVF clinics in major European and Middle Eastern markets was a key aspect of our KOL strategy. We are heartened that the KOLs we met recognised the need for an improved sperm selection and processing method to be developed and were eager to undertake a range of *in-vitro* studies with our Felix device."

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.